Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers
- PMID: 35884584
- PMCID: PMC9320734
- DOI: 10.3390/cancers14143524
Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers
Abstract
Hepatobiliary, pancreatic, and gastrointestinal cancers account for 36% of the ten million deaths caused by cancer worldwide every year. The two main reasons for this high mortality are their late diagnosis and their high refractoriness to pharmacological treatments, regardless of whether these are based on classical chemotherapeutic agents, targeted drugs, or newer immunomodulators. Mechanisms of chemoresistance (MOC) defining the multidrug resistance (MDR) phenotype of each tumor depend on the synergic function of proteins encoded by more than one hundred genes classified into seven groups (MOC1-7). Among them, the efflux of active agents from cancer cells across the plasma membrane caused by members of the superfamily of ATP-binding cassette (ABC) proteins (MOC-1b) plays a crucial role in determining tumor MDR. Although seven families of human ABC proteins are known, only a few pumps (mainly MDR1, MRP1-6, and BCRP) have been associated with reducing drug content and hence inducing chemoresistance in hepatobiliary, pancreatic, and gastrointestinal cancer cells. The present descriptive review, which compiles the updated information on the expression of these ABC proteins, will be helpful because there is still some confusion on the actual relevance of these pumps in response to pharmacological regimens currently used in treating these cancers. Moreover, we aim to define the MOC pattern on a tumor-by-tumor basis, even in a dynamic way, because it can vary during tumor progression and in response to chemotherapy. This information is indispensable for developing novel strategies for sensitization.
Keywords: ATP-binding cassette protein; anticancer drug; drug refractoriness; multidrug resistance; transport.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures
Similar articles
-
Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.Int J Cancer. 2002 Feb 20;97(6):751-60. doi: 10.1002/ijc.10131. Int J Cancer. 2002. PMID: 11857350
-
Poloxamines display a multiple inhibitory activity of ATP-binding cassette (ABC) transporters in cancer cell lines.Mol Pharm. 2011 Aug 1;8(4):1152-64. doi: 10.1021/mp2000132. Epub 2011 Jun 7. Mol Pharm. 2011. PMID: 21591727
-
Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.J Ethnopharmacol. 2017 May 5;203:110-119. doi: 10.1016/j.jep.2017.03.051. Epub 2017 Mar 28. J Ethnopharmacol. 2017. PMID: 28363522
-
Multidrug resistance: molecular mechanisms and clinical relevance.Cancer Chemother Pharmacol. 1997;40 Suppl:S3-8. doi: 10.1007/s002800051053. Cancer Chemother Pharmacol. 1997. PMID: 9272126 Review.
-
Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.Biomed Pharmacother. 2018 Apr;100:335-348. doi: 10.1016/j.biopha.2018.02.038. Epub 2018 Feb 16. Biomed Pharmacother. 2018. PMID: 29453043 Review.
Cited by
-
Characterization of Chemoresistance in Pancreatic Cancer: A Look at MDR-1 Polymorphisms and Expression in Cancer Cells and Patients.Int J Mol Sci. 2024 Aug 4;25(15):8515. doi: 10.3390/ijms25158515. Int J Mol Sci. 2024. PMID: 39126083 Free PMC article.
-
Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.MedComm (2020). 2024 Jul 28;5(8):e671. doi: 10.1002/mco2.671. eCollection 2024 Aug. MedComm (2020). 2024. PMID: 39070179 Free PMC article. Review.
-
Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic Cancer.Int J Mol Sci. 2024 Jul 6;25(13):7438. doi: 10.3390/ijms25137438. Int J Mol Sci. 2024. PMID: 39000545 Free PMC article.
-
Dysregulation of a Subset of Circulating and Vesicle-Associated miRNA in Pancreatic Cancer.Noncoding RNA. 2024 May 1;10(3):29. doi: 10.3390/ncrna10030029. Noncoding RNA. 2024. PMID: 38804361 Free PMC article.
-
Impact of ABCB1 and ABCG2 Transporter in Outcome of Gallbladder Cancer.J Clin Exp Hepatol. 2024 Sep-Oct;14(5):101410. doi: 10.1016/j.jceh.2024.101410. Epub 2024 Apr 12. J Clin Exp Hepatol. 2024. PMID: 38716375
References
-
- Marin J.J.G., Perez-Silva L., Macias R.I.R., Asensio M., Peleteiro-Vigil A., Sanchez-Martin A., Cives-Losada C., Sanchon-Sanchez P., Sanchez De Blas B., Herraez E., et al. Molecular bases of mechanisms accounting for drug resistance in gastric adenocarcinoma. Cancers. 2020;12:2116. doi: 10.3390/cancers12082116. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources